Business
OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma
NEW YORK, June 06, 2025--OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has submitted a request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. RMAT designations are granted to sponsors with regenerative medicine therapies for ser
About this update from Os Therapies Incorporated
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/6478565693ed683f13b284012b29c735"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DMUbmlwYv6tTDHBihoDGgg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6478565693ed683f13b284012b29c735","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/vn6KBsb8KRV8IcZ8JatUCQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/6478565693ed683f13b284012b29c735","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"If awarded, OST-HER2 would become the first listeria investigational medicinal product to be awarded the RMAT designation","length":121,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"RMAT designation reduces BLA application review time and permits augmented interactions with FDA to inform market access","length":120,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":241,"olType":false},{"type":"text","content":"NEW YORK, June 06, 2025--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has submitted a request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. RMAT designations are granted to sponsors with regenerative medicine therapies for serious or life-threatening conditions and provide sponsors with various benefits, including eligibility for an accelerated Biologics License Application (BLA) review.","length":701,"tagName":"p"},{"type":"text","content":"OST-HER2 has already received Rare Pediatric Disease Designation (RPDD), Orphan Drug Designation (ODD) and Fast Track Designation (FTD) for osteosarcoma from the U.S. FDA. If OST-HER2 receives a conditional BLA via Accelerated Review prior to September 30, 2026, the Company will become eligible to receive a Priority Review Voucher (PRV) that it intends to immediately sell. The m...